Evidence map›Paper›PMID 28074232›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2017

Vasoactive actions of nitroxyl (HNO) are preserved in resistance arteries in diabetes.

Marianne Tare, Rushita S R Kalidindi, Kristen J Bubb, Helena C Parkington, Wee-Ming Boon, Xiang Li, Christopher G Sobey, Grant R Drummond, Rebecca H Ritchie, Barbara K Kemp-Harper

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Marianne TareCardiovascular Disease Program, Biomedicine Discovery Institute, Department of Physiology, Monash University, Melbourne, VIC, 3800, Australia.
Rushita S R KalidindiCardiovascular Disease Program, Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Melbourne, VIC, 3800, Australia.
Kristen J BubbCardiovascular Disease Program, Biomedicine Discovery Institute, Department of Physiology, Monash University, Melbourne, VIC, 3800, Australia.
Helena C ParkingtonCardiovascular Disease Program, Biomedicine Discovery Institute, Department of Physiology, Monash University, Melbourne, VIC, 3800, Australia.
Wee-Ming BoonCardiovascular Disease Program, Biomedicine Discovery Institute, Department of Physiology, Monash University, Melbourne, VIC, 3800, Australia.
Xiang LiCardiovascular Disease Program, Biomedicine Discovery Institute, Department of Physiology, Monash University, Melbourne, VIC, 3800, Australia.
Christopher G SobeyCardiovascular Disease Program, Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Melbourne, VIC, 3800, Australia.
Grant R DrummondCardiovascular Disease Program, Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Melbourne, VIC, 3800, Australia.
Rebecca H RitchieBaker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia.
Barbara K Kemp-HarperCardiovascular Disease Program, Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Melbourne, VIC, 3800, Australia. barbara.kemp@monash.edu.
Australian Regenerative Medicine Institute · AUMonash University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endothelial dysfunction is a major risk factor for the vascular complications of diabetes. Increased reactive oxygen species (ROS) generation, a hallmark of diabetes, reduces the bioavailability of endothelial vasodilators, including nitric oxide (NO·). The vascular endothelium also produces the one electron reduced and protonated form of NO·, nitroxyl (HNO). Unlike NO·, HNO is resistant to scavenging by superoxide anions (·O

Indexed as

AnimalsDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Femoral ArteryIn Vitro TechniquesMaleMesenteric ArteriesNitrogen OxidesRats, WistarSuperoxidesVasodilator AgentsNitrogen OxidesnitroxylSuperoxidesVasodilator AgentsDiabetesEndothelium-dependent relaxationNitric oxideNitroxylVascular

Identifiers

PMID28074232
OpenAlexW2570570337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.